Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

5.69USD
31 Dec 2018
Change (% chg)

$0.50 (+9.63%)
Prev Close
$5.19
Open
$5.25
Day's High
$5.82
Day's Low
$5.25
Volume
100,934
Avg. Vol
78,783
52-wk High
$6.49
52-wk Low
$1.46

Latest Key Developments (Source: Significant Developments)

Imprimis Pharmaceuticals Q3 Loss Per Share $0.12
Tuesday, 13 Nov 2018 04:01pm EST 

Nov 13 (Reuters) - Imprimis Pharmaceuticals Inc ::IMPRIMIS PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 RESULTS.Q3 REVENUE ROSE 66 PERCENT TO $10.7 MILLION.QTRLY LOSS PER SHARE $0.12.QTRLY GROSS MARGIN INCREASED TO 61% FROM 48% IN Q3 2017.  Full Article

Imprimis Pharma Says Provided Notice Of Termination To Cantor Fitzgerald Of Controlled Equity Offering Sales Agreement
Tuesday, 6 Nov 2018 07:29am EST 

Nov 6 (Reuters) - Imprimis Pharmaceuticals Inc ::IMPRIMIS PHARMA - PROVIDED NOTICE OF TERMINATION TO CANTOR FITZGERALD OF CONTROLLED EQUITY OFFERING (SM) SALES AGREEMENT, DATED NOVEMBER 27, 2015.IMPRIMIS PHARMACEUTICALS INC - TERMINATION WILL BECOME EFFECTIVE ON NOVEMBER 15, 2018.IMPRIMIS - TERMINATING AGREEMENT AS CO ESTIMATES CASH FLOW PROVIDED BY OPERATIONS WILL BE SUFFICIENT TO FUND REQUIREMENTS FOR AT LEAST NEXT 12 MONTHS.  Full Article

Imprimis Pharmaceuticals Q1 Revenue Rose 45 Pct To $8.9 Million
Tuesday, 15 May 2018 04:01pm EDT 

May 15 (Reuters) - Imprimis Pharmaceuticals Inc ::IMPRIMIS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 RESULTS.Q1 REVENUE ROSE 45 PERCENT TO $8.9 MILLION.  Full Article

Imprimis Pharmaceuticals Q4 Revenue $7.3 Million
Thursday, 8 Mar 2018 04:01pm EST 

March 8 (Reuters) - Imprimis Pharmaceuticals Inc ::IMPRIMIS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER 2017 RESULTS.Q4 REVENUE ROSE 27 PERCENT TO $7.3 MILLION.  Full Article

Imprimis Pharmaceuticals Q3 loss per share $‍0.28​
Tuesday, 14 Nov 2017 04:01pm EST 

Nov 14 (Reuters) - Imprimis Pharmaceuticals Inc :Imprimis Pharmaceuticals announces third quarter 2017 results.Q3 revenue rose 34 percent to $6.5 million.Imprimis Pharmaceuticals inc qtrly loss per share $‍0.28​.  Full Article

FDA Curcumin Investigation supports Imprimis statement
Thursday, 14 Sep 2017 08:00am EDT 

Sept 14 (Reuters) - Imprimis Pharmaceuticals Inc :FDA Curcumin Investigation supports Imprimis statement.Imprimis Pharmaceuticals Inc - ‍provided an update regarding FDA Medwatch notice issued on August 4, 2017​.Imprimis Pharmaceuticals-confirms that upon discovery of supplier's mislabeling, it immediately terminated its business relationship with supplier​.Imprimis Pharmaceuticals Inc - will continue to review its operating procedures and make changes where appropriate to protect patient safety​.  Full Article

Imprimis Pharmaceuticals ‍responded to Allergan Plc press release regarding lawsuit
Monday, 11 Sep 2017 07:30am EDT 

Sept 11 (Reuters) - Allergan Plc :Imprimis Pharmaceuticals Inc - ‍responded to a press release issued by Allergan Plc regarding a lawsuit Allergan USA, Inc. filed against Imprimis​.Imprimis Pharmaceuticals Inc says will defend itself against Allergan's lawsuit​.  Full Article

Allergan USA files suits against Imprimis, Prescriber's Choice and Sincerus Florida
Thursday, 7 Sep 2017 08:53pm EDT 

Sept 7 (Reuters) - Allergan Plc :Allergan files suits against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC.Says Allergan USA filed lawsuits against Imprimis Pharmaceuticals, Prescriber's Choice, and Sincerus Florida.Allergan USA's lawsuit alleges that the companies are unlawfully manufacturing and selling unapproved new drugs.Lawsuit alleges that the co's are violating lanham act and state law by false and misleading advertising, promotion of unapproved new drugs.  Full Article

Imprimis Pharmaceuticals Q2 earnings per share $0.07
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Imprimis Pharmaceuticals Inc :Imprimis pharmaceuticals announces second quarter 2017 financial results.Q2 revenue rose 40 percent to $6.9 million.Q2 earnings per share $0.07.  Full Article

Imprimis provides statement regarding curcumin emulsion FDA medwatch notice
Monday, 7 Aug 2017 08:00am EDT 

Aug 7 (Reuters) - Imprimis Pharmaceuticals Inc :Imprimis statement regarding curcumin emulsion FDA medwatch notice.Imprimis Pharmaceuticals - believe events occurred due to allergic or hypersensitivity reactions to a product the patients likely should never have been administered.Imprimis Pharmaceuticals - co did not receive prescription orders for & did not dispense any product to either of patients referenced in notice​.Imprimis - it appears in both cases, without co's knowledge, professionals wrote prescription for specific patient, then used dispensed drug on different patient.  Full Article